Jushi Holdings (JUSHF) Income from Continuing Operations (2021 - 2026)
Jushi Holdings (JUSHF) posted quarterly Income from Continuing Operations of 7329000.0 for Q2 2026, up 40.56% year-over-year from 5213979.06 in Q2 2025, and up 63.07% quarter-over-quarter from 19847000.0 in Q1 2026.
Jushi Holdings (JUSHF) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Jushi Holdings (JUSHF) has reported Income from Continuing Operations for 6 consecutive years, with 7329000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Income from Continuing Operations rose 40.56% year-over-year to 7329000.0; the TTM figure through Jun 2026 stood at 66421000.0 (down 14.86% YoY), while the FY2025 annual figure was 68591000.0, down 40.62% from the prior year.
- Income from Continuing Operations rose to 7329000.0 in Q2 2026 per JUSHF's latest filing, from 19847000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 12066000.0 in Q2 2022 and bottomed at 139937000.0 in Q4 2022.
- Historically, Income from Continuing Operations has averaged 22887222.22 across 5 years, with a median of 16515500.0 in 2024.
- On a YoY basis, Income from Continuing Operations climbed as much as 357.74% in 2022 and fell as far as 2353.05% in 2022.
- Jushi Holdings' Income from Continuing Operations stood at 139937000.0 in 2022, then soared by 87.13% to 18004000.0 in 2023, then soared by 30.75% to 12468000.0 in 2024, then declined by 24.77% to 15556000.0 in 2025, then jumped by 52.89% to 7329000.0 in 2026.
- Business Quant data shows JUSHF's Income from Continuing Operations at 7329000.0 in Q2 2026, 19847000.0 in Q1 2026, and 15556000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | Jushi Holdings | 83.87 Mn | 50.54 Mn | 31.53 Mn | -7.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.33 Mn |
| Mar 31, 2026 | -19.85 Mn |
| Dec 31, 2025 | -15.56 Mn |
| Sep 30, 2025 | -23.69 Mn |
| Jun 30, 2025 | -12.33 Mn |
| Mar 31, 2025 | -17.02 Mn |
| Dec 31, 2024 | -12.47 Mn |
| Sep 30, 2024 | -16.02 Mn |
| Jun 30, 2024 | -1.94 Mn |
| Mar 31, 2024 | -18.36 Mn |
| Dec 31, 2023 | -18.00 Mn |
| Sep 30, 2023 | -20.62 Mn |
| Jun 30, 2023 | -14.04 Mn |
| Mar 31, 2023 | -12.44 Mn |
| Dec 31, 2022 | -139.94 Mn |
| Sep 30, 2022 | -54.70 Mn |
| Jun 30, 2022 | 12.07 Mn |
| Mar 31, 2022 | -19.76 Mn |
| Dec 31, 2021 | 6.21 Mn |
| Sep 30, 2021 | 39.68 Mn |